Monoclonal Antibodies
Genmab Announces Encouraging Preclinical Data for ofatumumab
Published in Drug Week, September 21st, 2007
Genmab A/S (OMX: GEN) announced that ofatumumab (HuMax-CD20(R)) appeared more effective at inducing complement dependent cytotoxicity (CDC), an immune system killing mechanism, than rituximab in a pre-clinical study. The CD20 antibodies were incubated with tumor cells and analyzed using Spinning Disk Confocal Fluorescent Microscopy. This technology allows imaging of the effects on target cells induced by therapeutic antibodies in real time. Both antibodies were found to activate CDC and induced profound changes in both shape and appearance of target cells.
Direct comparisons of ofatumumab and rituximab revealed ofatumumab to induce much more rapid and profound CDC and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-09-21)
More Articles from Drug Week
- Asthma
Childhood asthma still inappropriately treated in the UK - Breast Cancer
13 Percent of Women Stop Taking Breast Cancer Drug Because of Side Effects - Breast Cancer
Exercise and yoga improves quality of life in women with early-stage breast cancer - Cancer
Fat transforms vitamin C from 'good cop' into 'bad cop' - Cancer
Promising drug combination may help those with ocular melanoma that has spread - Cancer Vaccines
Novel HIV Vaccine Created at The Wistar Institute Funded for Clinical Development - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
